Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: review
- PMID: 1660184
- DOI: 10.1093/clinids/13.5.926
Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: review
Abstract
Although rates of seroconversion following administration of trivalent oral poliovirus vaccine (TOPV) approach 100% in industrialized countries, only 73% (range, 36%-99%) and 70% (range, 40%-99%) of children in developing countries have detectable antibody to poliovirus types 1 and 3, respectively, after three doses. While factors accounting for these differences have not been fully elucidated, available data suggest that type 2 vaccine virus and enteric pathogens often interfere with responses to types 1 and 3 vaccine viruses but that this interference may be overcome by modifying the absolute and relative dosage of the three Sabin types. Increasing the interval between doses beyond 30 days may also be important, in view of the prolonged excretion of vaccine virus and the potential for interference with responses to subsequent doses. Although advances in molecular biology may ultimately lead to the development of more-immunogenic vaccine candidates, approaches such as increasing the number of doses of TOPV, mass vaccination campaigns, and combined use of oral and inactivated vaccines should also be considered.
Similar articles
-
Immunogenicity and safety evaluation of bivalent types 1 and 3 oral poliovirus vaccine by comparing different poliomyelitis vaccination schedules in China: A randomized controlled non-inferiority clinical trial.Hum Vaccin Immunother. 2017 Jun 3;13(6):1-10. doi: 10.1080/21645515.2017.1288769. Epub 2017 Mar 1. Hum Vaccin Immunother. 2017. PMID: 28362135 Free PMC article. Clinical Trial.
-
Immunogenicity of a supplemental dose of oral versus inactivated poliovirus vaccine.Lancet. 1993 Jun 19;341(8860):1545-50. doi: 10.1016/0140-6736(93)90693-b. Lancet. 1993. PMID: 8099637 Clinical Trial.
-
Lessons from Cuba: mass campaign administration of trivalent oral poliovirus vaccine and seroprevalence of poliovirus neutralizing antibodies.Bull World Health Organ. 1994;72(2):221-5. Bull World Health Organ. 1994. PMID: 8205641 Free PMC article.
-
Global eradication of poliomyelitis: reinvent the wheel or use existing options effectively?Public Health Rev. 1993-1994;21(1-2):143-50. Public Health Rev. 1993. PMID: 8041881 Review.
-
Sabin monovalent oral polio vaccines: review of past experiences and their potential use after polio eradication.Clin Infect Dis. 2001 Aug 15;33(4):531-41. doi: 10.1086/321905. Epub 2001 Jul 9. Clin Infect Dis. 2001. PMID: 11462191 Review.
Cited by
-
Estimating the risk of re-emergence after stopping polio vaccination.Front Microbiol. 2012 May 21;3:178. doi: 10.3389/fmicb.2012.00178. eCollection 2012. Front Microbiol. 2012. PMID: 22783231 Free PMC article.
-
Chronic immune activation associated with chronic helminthic and human immunodeficiency virus infections: role of hyporesponsiveness and anergy.Clin Microbiol Rev. 2004 Oct;17(4):1012-30, table of contents. doi: 10.1128/CMR.17.4.1012-1030.2004. Clin Microbiol Rev. 2004. PMID: 15489359 Free PMC article. Review.
-
Review of use of inactivated poliovirus vaccine in campaigns to control type 2 circulating vaccine derived poliovirus (cVDPV) outbreaks.Vaccine. 2023 Apr 6;41 Suppl 1(Suppl 1):A113-A121. doi: 10.1016/j.vaccine.2022.03.027. Epub 2022 Mar 29. Vaccine. 2023. PMID: 35365341 Free PMC article. Review.
-
Rapid Disappearance of Poliovirus Type 2 (PV2) Immunity in Young Children Following Withdrawal of Oral PV2-Containing Vaccine in Vietnam.J Infect Dis. 2019 Jul 2;220(3):386-391. doi: 10.1093/infdis/jiz124. J Infect Dis. 2019. PMID: 30869149 Free PMC article.
-
Immune system development varies according to age, location, and anemia in African children.Sci Transl Med. 2020 Feb 5;12(529):eaaw9522. doi: 10.1126/scitranslmed.aaw9522. Sci Transl Med. 2020. PMID: 32024802 Free PMC article.